<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01673555</url>
  </required_header>
  <id_info>
    <org_study_id>116008</org_study_id>
    <nct_id>NCT01673555</nct_id>
  </id_info>
  <brief_title>Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to explore whether short-term therapy with GSK1278863 affects PASP&#xD;
      under normoxic and hypoxic conditions in healthy volunteers. Healthy subjects will be&#xD;
      evaluated using echocardiography to estimate PASP based on the velocity of the tricuspid&#xD;
      regurgitant jet. Resting PASP will be assessed under normoxic (room air) conditions, as well&#xD;
      as after 30 minutes' exposure to 15% O2 before, during, and after short-term treatment with&#xD;
      GSK1278863.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, placebo-controlled, single-blinded (subjects and&#xD;
      investigators will be blinded, GSK internal personnel will not be blinded) study designed to&#xD;
      test whether short-term administration (5 days) of GSK1278863 affects PASP under normoxic and&#xD;
      hypoxic conditions in healthy volunteers. Approximately 45 healthy subjects with&#xD;
      mild-moderate baseline tricuspid regurgitation (sufficient to allow reliable assessment of&#xD;
      PASP) will be enrolled into this study and will provide ~15 evaluable subjects in each arm&#xD;
      [Placebo, 5 mg, and 100 mg GSK 1278863].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2012</start_date>
  <completion_date type="Actual">November 19, 2012</completion_date>
  <primary_completion_date type="Actual">November 19, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-adjusted change from baseline in PASP (estimated by transthoracic echocardiography) under normoxic conditions following 5 days of GSK1278863</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placebo-adjusted change from baseline in PASP under normoxic and hypoxic conditions 8 hours after the first dose of study treatment</measure>
    <time_frame>Day 1</time_frame>
    <description>8 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-adjusted change from baseline in PASP under normoxic and hypoxic conditions following 1 day of therapy</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-adjusted change from baseline in PASP under normoxic and hypoxic conditions 8 hours after the fifth dose of study treatment</measure>
    <time_frame>Day 5</time_frame>
    <description>8 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-adjusted change from baseline in PASP under hypoxic conditions following 5 days of GSK1278863</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety and tolerability data including AE reporting, ECGs, vital signs, physical exam findings and clinical laboratory values, including hematologic parameters</measure>
    <time_frame>Day 5</time_frame>
    <description>Through-out the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (AUC, Cmax, Tmax, T1/2, etc.) of GSK1278863 and its circulating metabolites (M2, M3, M4, M5, M6 and M13)</measure>
    <time_frame>Day 5</time_frame>
    <description>Through-out the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV size, RV ejection fraction, severity of tricuspid regurgitation, right ventricular outflow tract acceleration time at all time points at which echocardiograms are obtained (as data permit)</measure>
    <time_frame>Day 5</time_frame>
    <description>Exploratory outcomes; through-out the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker/PD endpoints may include EPO, endothelin-1 and hepcidin or other markers of PHD or HIF activity, as data permit</measure>
    <time_frame>Day 5</time_frame>
    <description>Exploratory outcomes; through-out the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>GSK1278863 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1278863 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1278863 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1278863 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1278863</intervention_name>
    <description>GSK1278863</description>
    <arm_group_label>GSK1278863 100mg</arm_group_label>
    <arm_group_label>GSK1278863 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin less than and equal to 1.5xULN (isolated&#xD;
             bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct&#xD;
             bilirubin less than 35%).&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including [medical history, physical examination and laboratory tests]. A&#xD;
             subject with a clinical abnormality or laboratory parameters outside the reference&#xD;
             range for the population being studied may be included only if the Investigator and&#xD;
             the GSK Medical Monitor agree that the finding is unlikely to introduce additional&#xD;
             risk and will not interfere with the study procedures.&#xD;
&#xD;
          -  A hemoglobin value at screening between 13.5- 16 g/dL.&#xD;
&#xD;
          -  Male subjects between 18 and 55 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the contraception methods listed in the protocol. This criterion must be followed from&#xD;
             the time of the first dose of study medication until the follow-up visit.&#xD;
&#xD;
          -  BMII less than and equal to 32 kg/m2&#xD;
&#xD;
          -  Single QTcB or QTcF less than 450 msec&#xD;
&#xD;
          -  Screening echocardiogram of at least good quality, without clinically significant&#xD;
             abnormalities, and with mild-moderate tricuspid regurgitation sufficient for the&#xD;
             reliable estimation of PASP, as determined by the echocardiography core laboratory or&#xD;
             responsible cardiologist.&#xD;
&#xD;
          -  Screening PASP within the normal range under normoxic conditions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  Any history of IV drug abuse.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: an&#xD;
             average weekly intake of greater than 14 drinks for males or greater than 7 drinks for&#xD;
             females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5&#xD;
             ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and GSK Medical&#xD;
             Monitor the medication will not interfere with the study procedures or compromise&#xD;
             subject safety.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Strong family history of malignancy.&#xD;
&#xD;
          -  Subjects with sickle cell trait.&#xD;
&#xD;
          -  History of pulmonary hypertension&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>August 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2012</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK1278863</keyword>
  <keyword>Pulmonary artery pressure</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116008</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116008</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116008</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116008</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116008</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116008</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116008</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

